Loading
A phase 3 trial of Trastuzumab pamirtecan, Doxorubicin, Paclitaxel / nab-paclitaxel in endometrial cancer, run by BioNTech SE, now recruiting.
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer is a phase 3 interventional study registered as NCT06340568 by BioNTech SE, with 480 participants planned, started 2025-06-10 and due to reach its primary completion in 2028-03. Interventions recorded: BNT323/DB-1303, Doxorubicin, Paclitaxel, Docetaxel. Conditions listed: Endometrial Cancer. No results are recorded here; the registry entry is the source.
Shares Advanced or recurrent endometrial cancer, Doxorubicin, Endometrial cancer, Paclitaxel / nab-paclitaxel.
Shares Trastuzumab pamirtecan, BioNTech, Antibody-drug conjugate (ADC).
Shares Trastuzumab pamirtecan, BioNTech, Antibody-drug conjugate (ADC).
Shares Advanced or recurrent endometrial cancer, Doxorubicin, Endometrial cancer, Paclitaxel / nab-paclitaxel.
Shares Advanced or recurrent endometrial cancer, Docetaxel, Endometrial cancer, Paclitaxel / nab-paclitaxel.
Shares Advanced or recurrent endometrial cancer, Doxorubicin, Endometrial cancer, Paclitaxel / nab-paclitaxel.
Shares Trastuzumab pamirtecan, Antibody-drug conjugate (ADC).
Shares Docetaxel, Endometrial cancer, Paclitaxel / nab-paclitaxel, Antibody-drug conjugate (ADC).